Abstract: The provision of technology for reducing the unpleasant taste of ibuprofen in ibuprofen-containing oral pharmaceutical formulations. An oral pharmaceutical formulation in which the unpleasant taste of ibuprofen is reduced, which contains (A) ibuprofen or salt thereof or solvate of these, and (B) magnesium oxide, wherein the mass ratio [(B)/(A)] of component (A) and component (B) is 0.2-1.5.

Abstract: Disclosed embodiments provide a method of improving systemic symptoms such as sensitivity to cold via an oral composition. The oral composition includes, as its effective component, a red vine leaf extract to improve a symptom selected from the group consisting of sensitivity to cold, general fatigue, general weariness, stiff shoulders, and neck stiffness.

Abstract: Disclosed embodiments provide a method of improving systemic symptoms such as sensitivity to cold via an oral composition. The oral composition includes, as its effective component, a red vine leaf extract to improve a symptom selected from the group consisting of sensitivity to cold, general fatigue, general weariness, stiff shoulders, and neck stiffness.

Abstract: The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive(PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive(PSA).

Abstract: The timed-release pharmaceutical preparation of the invention is characterized by having a core containing a drug and a water-swellable substance, and a film containing a water-insoluble polymer, a plasticizer, and a water-insoluble filler, the core being coated with the film. With the timed-release pharmaceutical preparation of the present invention, the drug-release-initiation time and the drug release rate after the initiation of drug release can be controlled as desired.

Abstract: The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive(PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive(PSA).

Abstract: The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive(PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive(PSA).

Abstract: The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive (PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive (PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive (PSA).

Abstract: A transdermal absorption promotion composition comprising the following components (a), (b), and (c) and a transdermal absorption preparation comprising the following components (a), (b), (c), and (d) are disclosed. (a) propylene glycol (b) a polyol fatty acid ester (c) lauromacrogol (d) a drug component The transdermal absorption promotion composition and transdermal absorption preparation not only exhibit an excellent transdermal absorption promotion effect, but also exhibit superior skin-permeability, even if a drug having a relatively high lipophilic property and poor transdermal absorbability is used, exhibit a favorable feeling of use, and are safe and stable.

Abstract: The present invention relates to powdery inhalant compositions, each of which contains a steroidal anti-inflammatory drug, a carrier and water and has a water activity at 25° C. of from 0.35 to 0.75. Each powdery inhalant composition according to the present invention is high in the delivery rate of its steroidal anti-inflammatory drug to an inhalation target site from the nasal cavities or oral cavity, that is, to the alveoli, the bronchioles, the bronchial tubes or the airway, and allows the steroidal anti-inflammatory to exhibit its superb therapeutic effects.

Abstract: Imidazole derivatives of the formula (1) or salts thereof, pharmaceuticals containing the derivatives or the salts, and intermediates for the synthesis of the derivatives or the salts (wherein R1 is lower alkyl; R2 is alkyl or aralkyl; and X1 is halogeno). These compounds exhibit G-CSF-like activities and can be substituted for G-CSF preparations.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: Disclosed herein are quinoline derivatives having dual mechanistic properties, referred to in this patent document as “acetylcholine enhancers”, i.e., compounds which evidence acetylcholinesterase (AChE) inhibition activity, and 5-HT3 receptor antagonist activity. A particularly preferred compound is 2-[2-(1-benzylpiperizin-4-yl)ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo [3,4-b] quinolin-1-one hemifumarate, referred to herein as Compound A (“Cm.A”).

Abstract: Described is an azole derivative represented by the following formula (1): wherein, R1 represents a substituted phenyl group, R2 and R3 each represents a fluorine atom, an alkyl group or the like, and R4 represents an alkyl group, or salt thereof; and a medicament comprising the derivative or salt as an effective ingredient. The compound according to the present invention exhibits excellent antimycotic action and has good aqueous solubility.

Abstract: An orally administrable uncompressed rapidly dissolving molded dosage form comprises a drug and either one or more saccharides or one saccharide and polyvinylpyrrolidone. Saccarides are chosen and used in proportion based on their solubilities. Methods for producing uncompressed rapidly dissolving solid preparations comprise mixing a drug and carriers according to the present invention and charging the mixture in a mold. Rapidly dissolving oral dosage forms facilitate administration of drugs to patients having a difficulty in swallowing such as children and the elderly.

Abstract: A preparation for oral administration which comprises S-(3-hydroxypropyl)-L-cysteine and one or more excipients, where the excipients do not cause discoloration of S-(3-hydroxypropyl)-L-cysteine is disclosled. According to an embodiment of the invention, the excipient may comprise a starch and/or a cyclodextrin. Typical starches used in the invention include corn starch, potato starch, wheat starch, and rice starch. Typical cyclodextrins used in the invention include &agr;-cyclodextrin, &bgr;-cyclodextrin, and &ggr;-cyclodextrin. Other excipients, such as saccharides, sugar alcohols and cellulose are not present in amounts that cause discoloration of the HPCY.

Abstract: This invention relates to an intra-articular preparation for the treatment of arthropathy, which comprises microcapsules of (a) a high-molecular substance, which has biodegradability and biocompatibility, and (b) a drug. When applied directly to a joint area, this preparation can achieve a high drug concentration at the target area, can inhibit occurrence of general side effect, and can maintain drug efficacy over a long term. The preparation can therefore alleviate the burden on the patient.

Abstract: This invention relates to a drug composition with a controlled drug release rate. The drug composition comprises: a matrix formed of the following ingredients (a) and (b): (a) a biodegradable, biocompatible high-molecular substance and/or polyvalent metal ions or polyvalent metal ion source, and (b) hyaluronic acid or a salt thereof; and a drug incorporated as an ingredient (c) in said matrix. The drug composition has biodegradability and biocompatibility, permits easy control of a release rate of the drug, and can persistently exhibit its pharmacological effect over a long time.

Abstract: Described is a 4-hydroxy-4-phenylpiperidine derivative represented by the following formula (1): [wherein, R1 and R2 are the same or different and each independently represents a hydrogen atom, a lower alkyl, or the like, R3 represents a hydrogen atom or a group —(CR4R5)n—Y (in which, R4 and R5 each represents a hydrogen atom or a lower alkyl group, Y represents a group —COOR6, —CONR7R8, —OR9 or —OCOR10 (in which R6, R9 and R10 each independently represents a hydrogen atom, a lower alkyl group, or the like, R7 and R8 are the same or different and each independently represents a hydrogen atom, a lower alkyl group, or the like), and n stands for 1 to 6)], or salt thereof. The compound exhibits excellent peripheral analgesic action.